AI Science Tracker

EPFL

3 discoveries from 2024 to 2025

Discoveries

BindCraft designs protein binders in one shot

An open AlphaFold2-based hallucination pipeline designs binders with reported experimental success rates of 10-100% across 12 targets, with affinities predominantly in the nanomolar range. The authors also demonstrated effects in cell assays and patient-derived samples; these are experimental results, not established clinical treatments. This entry uses the Nature publication date (27 August 2025); the preprint appeared in 2024.

Technology: BindCraft (AlphaFold2-based design)

Family AlphaFold: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Binders tested experimentally across 12 targets (receptors, allergens, de novo proteins, nucleases) with reported success rates of 10-100%, plus functional assays in patient-derived samples and cell assays.
  • Still unknown: The abstract gives no number of designs per target or per-target success rates, and states no limitations.
  • AI role: Open-source automated pipeline using AlphaFold2 weights to design binders in one shot, without high-throughput screening.

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-025-09429-6&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 454 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MaSIF designs binders for protein–drug complexes

MaSIF designed proteins that recognize three complexes containing progesterone, venetoclax, or actinonin, then validated them in the lab. A venetoclax-inducible system activated the antitumor activity of CAR T cells in vitro; this is a proof of concept without clinical validation.

Technology: MaSIF (deep learning on molecular surfaces)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: MaSIF-designed binders were validated in the lab against three drug-bound complexes, and a venetoclax-inducible system switched on CAR-T tumor-killing activity in vitro.
  • Still unknown: The source states the CAR-T work is in vitro only, with no clinical validation, and binding sites are hard to predict.
  • AI role: MaSIF generated surface fingerprints and searched for complementary protein surfaces to design binders.

Evidence sources: https://actu.epfl.ch/news/a-deep-learning-pipeline-for-controlling-protein-3/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 93 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Human-guided active learning improves nickel-cobalt methanation tests

A human-in-the-loop model selected nickel-cobalt catalysts and reaction settings for a 48-test laboratory campaign. Further selected experiments improved methane space-time yield by nearly 50% over the previous maximum in that dataset. Extrapolation remained harder than interpolation. This is a bounded catalyst-and-condition result, not evidence of industrial deployment or lifecycle climate benefit.

Technology: Gaussian-process active learning with batch acquisition

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Selected catalysts and conditions were experimentally tested; model-suggested activity trends received follow-up.
  • Still unknown: Generality, industrial durability and lifecycle carbon benefit were not established.
  • AI role: Gaussian-process active learning with batch acquisition supported the stated study; experimental and interpretive work remained with researchers.

Evidence sources: https://pubs.rsc.org/en/content/articlehtml/2024/cy/d4cy00873a

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Indexed primary publisher abstract, model Methods, selected Results, affiliations and first-online date; supplementary material not reviewed..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.